

27<sup>th</sup> February 2022

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

Dear Sir/Madam,

**Sub: Clarification on the news item appearing in “economictimes.indiatimes.com” dated 24<sup>th</sup> February 2022**

This has reference to your email and letter dated 25<sup>th</sup> February 2022 seeking clarification regarding recent news item which appeared in the “economictimes.indiatimes.com” dated 24<sup>th</sup> February 2022 captioned “Cipla has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct local trials on anti-Covid-19 pill Paxlovid”. Our response on the same is as follows:

**Query 1.**

**Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.**

We confirm that the Company has received an approval from the Subject Expert Committee (“SEC”) of the Central Drugs Standard Control Organization (“CDSCO”) to conduct local trials on anti Covid-19 pill Paxlovid on 24<sup>th</sup> February 2022.

Cipla Limited is the third Company which has been granted such approval by CDSCO. Basis the approval, the Company will conduct Bioavailability and Bioequivalence (“BA/BE”) studies and submit safety data for review as per requisite timelines.

Approvals received from the regulator for conducting local trials on drugs is not a material information. It is part of the Company’s routine operational matter and is non-exclusive in nature, and therefore response to the other part of the query does not entail.

### **Query 2**

**Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.**

The Company is not aware of any information that has not been announced to the Exchanges which could explain the movement in the trading of shares. We have observed that due to the ongoing geopolitical issue, the Global and Indian indices have witnessed volatile movements over the last few days which in turn reflected in the share prices across many companies. The Company has no control over the active trading in the shares of the Company, as the same is purely market driven and a culmination of various global and economic factors.

As explained in our reply to query no. 1, such approvals received from regulators for conducting local trials on drugs are routine operational matters for the Company and does not qualify as a material information under the criteria stated in the Company's Policy for determination of materiality of events or information ("Policy") as well as under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and accordingly, did not require any stock exchange intimation.

### **Query 3**

**The material impact of this article on the Company.**

To the best of our understanding the news article had no material impact on the Company.

We assure you that the Company follows highest standards of governance and compliance norms, and timely disclosures are made to the stock exchanges under applicable regulations including Regulation 30 of the Listing Regulations.

This is for your information and records.

Thanking you

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Simona Dsouza